Page 82 - HIV/AIDS Guidelines

References

1. GulickRM,RibaudoHJ,ShikumaCM,etal.Three-vsfour-drugantiretroviralregimensfortheinitialtreatmentofHIV-
1infection:arandomizedcontrolledtrial.JAMA.Aug162006;296(7):769-781.

2. GallantJE,StaszewskiS,PozniakAL,etal.EfficacyandsafetyoftenofovirDFvsstavudineincombinationtherapyin
antiretroviral-naivepatients:a3-yearrandomizedtrial.JAMA.Jul142004;292(2):191-201.

3. StaszewskiS,Morales-RamirezJ,TashimaKT,etal.Efavirenzpluszidovudineandlamivudine,efavirenzplusindinavir,
andindinavirpluszidovudineandlamivudineinthetreatmentofHIV-1infectioninadults.Study006Team.N Engl J
Med.Dec161999;341(25):1865-1873.
4. RiddlerSA,HaubrichR,DiRienzoAG,etal.Class-sparingregimensforinitialtreatmentofHIV-1infection.N Engl J
Med.May152008;358(20):2095-2106.
5. SquiresK,LazzarinA,GatellJM,etal.Comparisonofonce-dailyatazanavirwithefavirenz,eachincombinationwith
fixed-dosezidovudineandlamivudine,asinitialtherapyforpatientsinfectedwithHIV.J Acquir Immune Defic Syndr.
Aug152004;36(5):1011-1019.
6. LennoxJL,DeJesusE,LazzarinA,etal.Safetyandefficacyofraltegravir-basedversusefavirenz-basedcombination
therapyintreatment-naivepatientswithHIV-1infection:amulticentre,double-blindrandomisedcontrolledtrial.Lancet.
Sep52009;374(9692):796-806.
7. CooperDA,HeeraJ,GoodrichJ,etal.Maravirocversusefavirenz,bothincombinationwithzidovudine-lamivudine,for
thetreatmentofantiretroviral-naivesubjectswithCCR5-tropicHIV-1infection.J Infect Dis.Mar152010;201(6):803-813.
8. RobbinsGK,DeGruttolaV,ShaferRW,etal.Comparisonofsequentialthree-drugregimensasinitialtherapyforHIV-1
infection.N Engl J Med.Dec112003;349(24):2293-2303.
9. SierraMaderoJ,VillasisA,MendezP,etal.Aprospective,randomized,openlabeltrialofefavirenzversus
lopinavir/ritonavirbasedHAARTamongantiretroviraltherapynaive,HIVinfectedindividualspresentingforcarewithCD4
3
cellcounts<200/mm .Paperpresentedat:17thInternationalAIDSConference;August3-8,2008;MexicoCity,Mexico.
10. HaubrichRH,RiddlerSA,DiRienzoAG,etal.Metabolicoutcomesinarandomizedtrialofnucleoside,nonnucleoside
andproteaseinhibitor-sparingregimensforinitialHIVtreatment.AIDS.Jun12009;23(9):1109-1118.
11. HirschMS,GunthardHF,SchapiroJM,etal.AntiretroviraldrugresistancetestinginadultHIV-1infection:2008
recommendationsofanInternationalAIDSSociety-USApanel.Clin Infect Dis.Jul152008;47(2):266-285.
12. KimD,WheelerW,ZiebellR,ale.Prevalenceoftransmittedantiretroviraldrugresistanceamongnewly-diagnosed
HIV-1-infectedpersons,US,2007.Paperpresentedat:17thConferenceonRetrovirusesandOpportunisticInfections
(CROI);February16-19,2010;SanFrancisco,CA.Abstract580.
13. RockstrohJK,LennoxJL,DejesusE,etal.Long-termtreatmentwithraltegravirorefavirenzcombinedwith
tenofovir/emtricitabinefortreatment-naivehumanimmunodeficiencyvirus-1-infectedpatients:156-weekresultsfrom
STARTMRK.Clin Infect Dis.Oct2011;53(8):807-816.

14. NovakRM,ChenL,MacArthurRD,etal.PrevalenceofantiretroviraldrugresistancemutationsinchronicallyHIV-
infected,treatment-naivepatients:implicationsforroutineresistancescreeningbeforeinitiationofantiretroviraltherapy.
Clin Infect Dis.Feb12005;40(3):468-474.
15. WensingAM,vandeVijverDA,AngaranoG,etal.Prevalenceofdrug-resistantHIV-1variantsinuntreatedindividuals
inEurope:implicationsforclinicalmanagement.J Infect Dis.Sep152005;192(6):958-966.
16. WeinstockHS,ZaidiI,HeneineW,etal.Theepidemiologyofantiretroviraldrugresistanceamongdrug-naiveHIV-1-
infectedpersonsin10UScities.J Infect Dis.Jun152004;189(12):2174-2180.
17. AndriesK,AzijnH,ThielemansT,etal.TMC125,anovelnext-generationnonnucleosidereversetranscriptaseinhibitor
activeagainstnonnucleosidereversetranscriptaseinhibitor-resistanthumanimmunodeficiencyvirustype1.Antimicrob
Agents Chemother.Dec2004;48(12):4680-4686.

Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents F-21

Downloaded from http://aidsinfo.nih.gov/guidelines on 12/8/2012 EST.